MedTrace Logo

Multiple Ascending Dose Noribogaine PK/PD in Healthy Volunteers

NCT06480981 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2026-01-22

Study results available
· View outcomes & findings →

Summary

This trial will be a randomised, double-blind, sequential-group, multiple-dose, placebo-controlled, dose escalation trial to characterise the pharmacokinetics (PK), pharmacodynamics (PD) and safety of noribogaine in healthy adult participants.

Conditions

  • Pharmacokinetics

Interventions

DRUG

Noribogaine

Noribogaine capsules

Sponsors & Collaborators

  • DemeRx NB

    lead INDUSTRY

Principal Investigators

  • Jorg Taubel · Richmond Pharmacology

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-06-20
Primary Completion
2024-12-23
Completion
2025-01-13

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06480981 on ClinicalTrials.gov